폐 선 암 세포에서 생체 외에서 2 단계 복용량 단계적 확대 절차와 EGFR TKI와 만난 TKI 듀얼 저항 설정

0:30

Determining Initial Gefitnib Concentration Using the 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenylterazolium Bromide (MTT) Assay

2:15

Continuous Stepwise Dose-escalation of Gefitnib Treatment of PC-9 Cells

3:31

Determine Initial Concentration of PHA665752 Using the MTT Assay

6:37

Results: Two-step Dose-escalation Procedure to Establish Dual Resistance to EGFT-TKI and MET-TKI

8:21

Conclusion